Daniel Wan-yui Chan

Q: What Schools Are Affiliated With Daniel Wan-yui Chan

Daniel Wan-yui Chan is affiliated with the following schools: University of New South Wales, Johns Hopkins University

Daniel Wan-yui Chan's AcademicInfluence.com Rankings

Daniel Wan-yui Chan

Philosophy

#6643

World Rank

#9709

Historical Rank

Logic

#3778

World Rank

#4986

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Daniel Wan-yui Chan's Degrees

Doctorate Medicine University of California, San Francisco
PhD Biomedical Sciences University of California, San Francisco

Why Is Daniel Wan-yui Chan Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Daniel Wan-yui Chan's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Natural history of progression after PSA elevation following radical prostatectomy. (1999) (2472)
The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. (1993) (1237)
Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. (1992) (1120)
Three Biomarkers Identified from Serum Proteomic Analysis for the Detection of Early Stage Ovarian Cancer (2004) (936)
Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. (2002) (928)
Overview of the HUPO Plasma Proteome Project: Results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core dataset of 3020 proteins and a publicly‐available database (2005) (766)
Integrated Proteogenomic Characterization of Human High-Grade Serous Ovarian Cancer (2016) (672)
Immunosensors--principles and applications to clinical chemistry. (2001) (643)
National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. (2008) (603)
Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. (1990) (594)
Standard operating procedures for serum and plasma collection: early detection research network consensus statement standard operating procedure integration working group. (2009) (585)
Natural History of Progression After PSA Elevation Following Radical Prostatectomy (1999) (568)
Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. (1988) (541)
HUPO Plasma Proteome Project specimen collection and handling: Towards the standardization of parameters for plasma proteome samples (2005) (509)
A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. (2011) (437)
Targeted Peptide Measurements in Biology and Medicine: Best Practices for Mass Spectrometry-based Assay Development Using a Fit-for-Purpose Approach* (2014) (430)
Proteogenomic Analysis of Human Colon Cancer Reveals New Therapeutic Opportunities (2019) (366)
Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility. (2005) (350)
Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges (2013) (346)
Multi-laboratory assessment of reproducibility, qualitative and quantitative performance of SWATH-mass spectrometry (2016) (346)
Increased plasma DNA integrity in cancer patients. (2003) (334)
Identification of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein I as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology. (2002) (308)
Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings. (1998) (293)
Ischemia in Tumors Induces Early and Sustained Phosphorylation Changes in Stress Kinase Pathways but Does Not Affect Global Protein Levels* (2014) (292)
Serum Diagnosis of Pancreatic Adenocarcinoma Using Surface-Enhanced Laser Desorption and Ionization Mass Spectrometry (2004) (288)
Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma (2019) (283)
Cardiac Troponin I Predicts Short-Term Mortality in Vascular Surgery Patients (2002) (263)
Serum Macrophage Inhibitory Cytokine 1 as a Marker of Pancreatic and Other Periampullary Cancers (2004) (260)
Reproducible workflow for multiplexed deep-scale proteome and phosphoproteome analysis of tumor tissues by liquid chromatography–mass spectrometry (2018) (256)
Hepatitis B and hepatitis C in emergency department patients. (1992) (254)
Estimation of prostatic growth using serial prostate-specific antigen measurements in men with and without prostate disease. (1992) (254)
Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: influence of total PSA, prostate volume, and age. (1996) (253)
Can urinary PCA3 supplement PSA in the early detection of prostate cancer? (2014) (234)
Plasma selenium level before diagnosis and the risk of prostate cancer development. (2001) (229)
Proteomic approaches to tumor marker discovery. (2002) (228)
The prostate health index selectively identifies clinically significant prostate cancer. (2015) (228)
Aberrant glycosylation associated with enzymes as cancer biomarkers (2011) (220)
Characterization of Renal Allograft Rejection by Urinary Proteomic Analysis (2003) (207)
Serum Markers in Patients with Resectable Pancreatic Adenocarcinoma: Macrophage Inhibitory Cytokine 1 versus CA19-9 (2006) (205)
A Prospective, Multicenter, National Cancer Institute Early Detection Research Network Study of [−2]proPSA: Improving Prostate Cancer Detection and Correlating with Cancer Aggressiveness (2010) (202)
HLA-G is a potential tumor marker in malignant ascites. (2003) (195)
Proteogenomic Characterization of Endometrial Carcinoma (2020) (194)
Advances in mass spectrometry-based clinical biomarker discovery (2016) (192)
Low levels of prostate-specific antigen predict long-term risk of prostate cancer: results from the Baltimore Longitudinal Study of Aging. (2001) (177)
Independent validation of candidate breast cancer serum biomarkers identified by mass spectrometry. (2005) (176)
Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer. (1997) (176)
Prostate-specific antigen as a marker for prostatic cancer: a monoclonal and a polyclonal immunoassay compared. (1987) (174)
Classification of cancer types by measuring variants of host response proteins using SELDI serum assays (2005) (173)
Influence of radical prostatectomy on serum hormone levels. (1998) (171)
Comprehensive analysis of protein glycosylation by solid-phase extraction of N-linked glycans and glycosite-containing peptides (2016) (166)
Recommendations for the Generation, Quantification, Storage, and Handling of Peptides Used for Mass Spectrometry-Based Assays. (2016) (162)
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in clinical practice: quality requirements. (2008) (161)
Biomarkers in prostate cancer: what's new? (2014) (159)
The Road from Discovery to Clinical Diagnostics: Lessons Learned from the First FDA-Cleared In Vitro Diagnostic Multivariate Index Assay of Proteomic Biomarkers (2010) (156)
Prostate-specific antigen variability in men without prostate cancer: effect of sampling interval on prostate-specific antigen velocity. (1995) (150)
Use of human glandular kallikrein 2 for the detection of prostate cancer: preliminary analysis. (1999) (147)
Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer. (2000) (144)
Assessment of plasma DNA levels, allelic imbalance, and CA 125 as diagnostic tests for cancer. (2003) (144)
Longitudinal evaluation of serum androgen levels in men with and without prostate cancer (1995) (140)
Multicenter Evaluation of the Prostate Health Index to Detect Aggressive Prostate Cancer in Biopsy Naïve Men. (2015) (137)
Complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trial. (2003) (137)
Use of percentage of free prostate-specific antigen to identify men at high risk of prostate cancer when PSA levels are 2.51 to 4 ng/mL and digital rectal examination is not suspicious for prostate cancer: an alternative model. (1999) (135)
SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancer. (2008) (130)
Glycoproteomics for prostate cancer detection: changes in serum PSA glycosylation patterns. (2009) (128)
Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: sources of sample bias. (2008) (124)
Proenzyme psa for the early detection of prostate cancer in the 2.5-4.0 ng/ml total psa range: preliminary analysis. (2003) (121)
The influence of reversible androgen deprivation on serum prostate-specific antigen levels in men with benign prostatic hyperplasia. (1989) (118)
Proteogenomic insights into the biology and treatment of HPV-negative head and neck squamous cell carcinoma. (2021) (118)
EPCA-2: a highly specific serum marker for prostate cancer. (2006) (113)
Identifying markers for pancreatic cancer by gene expression analysis. (1998) (112)
Association Between Combined TMPRSS2: ERG and PCA3 RNA Urinary Testing and Detection of Aggressive Prostate Cancer (2017) (111)
Quantification of fragments of human serum inter-alpha-trypsin inhibitor heavy chain 4 by a surface-enhanced laser desorption/ionization-based immunoassay. (2006) (110)
Use of Truquant BR radioimmunoassay for early detection of breast cancer recurrence in patients with stage II and stage III disease. (1997) (110)
Elevated serum human chorionic gonadotropin as evidence of secretory response in severe preeclampsia. (1994) (107)
The use of percent free prostate specific antigen for staging clinically localized prostate cancer. (1998) (105)
Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer. (2007) (105)
Fatty acid synthase (FAS) expression in human breast cancer cell culture supernatants and in breast cancer patients. (2001) (102)
Evaluation of proprostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0 to 10.0 ng/ml. (2003) (101)
Proteome Profiling Outperforms Transcriptome Profiling for Coexpression Based Gene Function Prediction* (2016) (101)
Proteogenomic characterization of pancreatic ductal adenocarcinoma (2021) (101)
Ovarian malignancy risk stratification of the adnexal mass using a multivariate index assay. (2013) (99)
A high-stringency blueprint of the human proteome (2020) (98)
Proteomics: a new diagnostic frontier. (2006) (98)
Percentage of free prostate-specific antigen in sera predicts aggressiveness of prostate cancer a decade before diagnosis. (1997) (97)
Recommendations for Mass Spectrometry Data Quality Metrics for Open Access Data (Corollary to the Amsterdam Principles)* (2011) (93)
An Analysis of the Sensitivity of Proteogenomic Mapping of Somatic Mutations and Novel Splicing Events in Cancer* (2015) (92)
Comparative analysis of complexed prostate specific antigen, free prostate specific antigen and their ratio in detecting prostate cancer. (2002) (92)
The clinical application of proteomics. (2005) (88)
Complexed prostate-specific antigen for early detection of prostate cancer in men with serum prostate-specific antigen levels of 2 to 4 nanograms per milliliter. (2002) (87)
Analysis of Human Proteome Organization Plasma Proteome Project (HUPO PPP) reference specimens using surface enhanced laser desorption/ionization‐time of flight (SELDI‐TOF) mass spectrometry: Multi‐institution correlation of spectra and identification of biomarkers (2005) (87)
[-2]proenzyme prostate specific antigen for prostate cancer detection: a national cancer institute early detection research network validation study. (2007) (85)
Prospective evaluation of percent free-PSA and complexed-PSA for early detection of prostate cancer (1998) (83)
Validation of a second-generation multivariate index assay for malignancy risk of adnexal masses. (2016) (81)
Identification of Biomarkers for Breast Cancer in Nipple Aspiration and Ductal Lavage Fluid (2005) (80)
Clinical utility of serum HER-2/neu testing on the Bayer Immuno 1 automated system in breast cancer. (2001) (80)
Elevated circulating thrombomodulin in severe preeclampsia. (1993) (79)
Cancer biomarker discovery and translation: proteomics and beyond (2019) (78)
Simultaneous analysis of glycosylated and sialylated prostate-specific antigen revealing differential distribution of glycosylated prostate-specific antigen isoforms in prostate cancer tissues. (2011) (77)
A proteogenomic portrait of lung squamous cell carcinoma (2021) (77)
Prostate Health Index improves multivariable risk prediction of aggressive prostate cancer (2017) (74)
Detection and verification of glycosylation patterns of glycoproteins from clinical specimens using lectin microarrays and lectin-based immunosorbent assays. (2011) (71)
Detection of prostate cancer using serum proteomics pattern in a histologically confirmed population. (2004) (70)
Longitudinal analysis of serial measurements of free and total PSA among men with and without prostatic cancer. (1996) (69)
Bioinformatics strategies for proteomic profiling. (2004) (68)
Prostate specific antigen predicts the long-term risk of prostate enlargement: results from the Baltimore Longitudinal Study of Aging. (2002) (66)
Immunoenzymetric assay for creatine kinase MB with subunit-specific monoclonal antibodies compared with an immunochemical method and electrophoresis. (1985) (65)
Platform for establishing interlaboratory reproducibility of selected reaction monitoring-based mass spectrometry peptide assays. (2010) (65)
Influence of finasteride on free and total serum prostate specific antigen levels in men with benign prostatic hyperplasia. (1998) (64)
Cancer Proteomics: Serum Diagnostics for Tumor Marker Discovery (2004) (64)
The Application of Clinical Proteomics to Cancer and other Diseases (2003) (64)
Initial analyses of colon cancer-specific antigen (CCSA)-3 and CCSA-4 as colorectal cancer-associated serum markers. (2007) (63)
Interlaboratory reproducibility of selective reaction monitoring assays using multiple upfront analyte enrichment strategies. (2012) (62)
The role of free/total prostate-specific antigen ratio in the prediction of final pathologic stage for men with clinically localized prostate cancer. (1996) (61)
Prospective multicenter evaluation of the Beckman Coulter Prostate Health Index using WHO calibration. (2013) (61)
Serum Fucosylated Prostate-specific Antigen (PSA) Improves the Differentiation of Aggressive from Non-aggressive Prostate Cancers (2015) (60)
Early Detection of Cancer: Immunoassays for Plasma Tumor Markers. (2009) (59)
Integrated Proteomic and Glycoproteomic Characterization of Human High-Grade Serous Ovarian Carcinoma. (2020) (58)
A highly sensitive targeted mass spectrometric assay for quantification of AGR2 protein in human urine and serum. (2014) (57)
Use of troponin T and creatine kinase-MB subunit levels for risk stratification of emergency department patients with possible myocardial ischemia. (1998) (56)
A comparative evaluation of Golgi protein-73, fucosylated hemopexin, α-fetoprotein, and PIVKA-II in the serum of patients with chronic hepatitis, cirrhosis, and hepatocellular carcinoma (2011) (54)
Clinical utility of proPSA and "benign" PSA when percent free PSA is less than 15%. (2004) (54)
Enzymes and related proteins as cancer biomarkers: a proteomic approach. (2007) (54)
Prostate-specific antigen. Its discovery and biochemical characteristics. (1997) (54)
Fifth-generation digital immunoassay for prostate-specific antigen by single molecule array technology. (2011) (54)
Fatty acid synthase as a tumor marker: its extracellular expression in human breast cancer. (2004) (54)
Cancer Proteomics: In Pursuit of “True” Biomarker Discovery (2005) (51)
Glycoproteomics-based signatures for tumor subtyping and clinical outcome prediction of high-grade serous ovarian cancer (2020) (51)
Capillary prolactin measurement for diagnosis of seizures (1991) (49)
Suppression of annexin A11 in ovarian cancer: implications in chemoresistance. (2009) (49)
Clinical performance of a multivariate index assay for detecting early-stage ovarian cancer. (2013) (48)
Intermittent cardiac troponin-I screening is an effective means of surveillance for a perioperative myocardial infarction. (2005) (47)
Proteomic cancer biomarkers from discovery to approval: it’s worth the effort (2014) (46)
Analysis of serum total and free PSA using immunoaffinity depletion coupled to SRM: correlation with clinical immunoassay tests. (2012) (46)
The human proteome – a scientific opportunity for transforming diagnostics, therapeutics, and healthcare (2012) (45)
Evaluation of a monoclonal immunoradiometric assay for prostate-specific antigen. (1987) (42)
Serum concentrations of cardiac troponin I in sudden death: a pilot study. (1998) (41)
The impact of prostate volume, number of biopsy cores and American Urological Association symptom score on the sensitivity of cancer detection using the Prostate Cancer Prevention Trial risk calculator. (2013) (40)
Annexin XI Is Associated with Cisplatin Resistance and Related to Tumor Recurrence in Ovarian Cancer Patients (2007) (40)
Molecular forms of prostate-specific antigen and human kallikrein 2 (hK2) in urine are not clinically useful for early detection and staging of prostate cancer. (1997) (39)
Cancer Biomarker Discovery in Plasma Using a Tissue-targeted Proteomic Approach (2007) (39)
Challenges and opportunities in the proteomic characterization of clear cell renal cell carcinoma (ccRCC): A critical step towards the personalized care of renal cancers. (2019) (38)
Assessing tumors in living animals through measurement of urinary β-human chorionic gonadotropin (2000) (38)
Evaluation of Colon Cancer–Specific Antigen 2 as a Potential Serum Marker for Colorectal Cancer (2008) (37)
Precision medicine: from pharmacogenomics to pharmacoproteomics (2016) (37)
Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma (2020) (36)
Tyramide signal amplification for antibody-overlay lectin microarray: a strategy to improve the sensitivity of targeted glycan profiling. (2011) (36)
Proteomic analysis of dunning prostate cancer cell lines with variable metastatic potential using SELDI‐TOF (2004) (36)
The relationship of prostate specific antigen levels and residual tumor volume in stage A prostate cancer. (1990) (35)
Serum acid phosphatase level and biochemical recurrence following radical prostatectomy for men with clinically localized prostate cancer. (2001) (35)
Thrombomodulin Levels in Preeclampsia, Gestational Hypertension, and Chronic Hypertension (1995) (34)
Multicenter comparison of the diagnostic performance of free prostate-specific antigen. (1996) (34)
Cardiac troponin T and C-reactive protein as markers of acute cardiac allograft rejection. (2001) (34)
Predicting prostate cancer biochemical recurrence using a panel of serum proteomic biomarkers. (2009) (34)
Short-term stability of the molecular forms of prostate-specific antigen and effect on percent complexed prostate-specific antigen and percent free prostate-specific antigen. (2002) (33)
Affinity chromatographic separation of alpha-fetoprotein variants: development of a mini-column procedure, and application to cancer patients. (1986) (33)
Proteogenomic Characterization of Ovarian HGSC Implicates Mitotic Kinases, Replication Stress in Observed Chromosomal Instability (2020) (33)
Two-site ELISA for the quantitative determination of fatty acid synthase. (2001) (33)
The potential utility of a rapid CK-MB assay in evaluating emergency department patients with possible myocardial infarction. (1991) (33)
Probability of prostate cancer detection based on results of a multicenter study using the AxSYM free PSA and total PSA assays. (2000) (32)
Clinical evaluation of the Elecsys CA 15-3 test in breast cancer patients. (2003) (32)
WHO first international standards for prostate-specific antigen: the beginning of the end for assay discrepancies? (2000) (32)
Predicting Ovarian Cancer Patients' Clinical Response to Platinum-Based Chemotherapy by Their Tumor Proteomic Signatures. (2016) (31)
The value of serum enzymatic acid phosphatase in the staging of localized prostate cancer. (1992) (31)
Using the CPTAC Assay Portal to Identify and Implement Highly Characterized Targeted Proteomics Assays. (2016) (30)
Analytical and clinical evaluation of an electrochemiluminescence immunoassay for the determination of CA 125. (1998) (29)
The prognostic significance of troponin I and troponin T. (1998) (29)
A new biomarker in monitoring breast cancer: CA 549. (1988) (29)
Comparison of predictive accuracy for pathologically organ confined clinical stage T1c prostate cancer using human glandular kallikrein 2 and prostate specific antigen combined with clinical stage and Gleason grade. (2005) (28)
Hybritech total and free prostate-specific antigen assays developed for the Beckman Coulter access automated chemiluminescent immunoassay system: a multicenter evaluation of analytical performance. (2001) (28)
Cancer proteomics (2006) (28)
Updating risk prediction tools: A case study in prostate cancer (2012) (28)
Protein signatures of molecular pathways in non-small cell lung carcinoma (NSCLC): comparison of glycoproteomics and global proteomics (2017) (27)
Multiplexed Targeted Mass Spectrometry-Based Assays for the Quantification of N-Linked Glycosite-Containing Peptides in Serum. (2015) (27)
Laboratory and bedside evaluation of portable glucose meters. (1995) (27)
Clinical analyzers. Immunoassays. (1999) (26)
Prostate specific antigen assay standardization bias could affect clinical decision making. (2008) (26)
Identification of glycoproteins containing specific glycans using a lectin-chemical method. (2015) (26)
Validation of a multiplex immunoassay for serum angiogenic factors as biomarkers for aggressive prostate cancer. (2012) (26)
Meaning of serum free-thyroxin values in nonthyroidal illnesses: seven methods compared. (1983) (25)
A multiplex immunoassay of serum biomarkers for the detection of uveal melanoma (2019) (25)
The binding of a synthetic progestin, R5020 to transcortin and serum albumin. (1977) (25)
Glycoproteomic analysis of bronchoalveolar lavage (BAL) fluid identifies tumor-associated glycoproteins from lung adenocarcinoma. (2013) (25)
Identification of Serum Biomarker Panels for the Early Detection of Pancreatic Cancer (2018) (24)
Integrated glycoprotein immobilization method for glycopeptide and glycan analysis of cardiac hypertrophy. (2015) (23)
Orthogonal Proteomic Platforms and Their Implications for the Stable Classification of High-Grade Serous Ovarian Cancer Subtypes (2019) (23)
Evaluation of a monoclonal immunoenzymometric assay for alpha-fetoprotein. (1986) (23)
Standardization of two immunoassays for human glandular kallikrein 2. (2003) (22)
Validation of a novel model for the early detection of hepatocellular carcinoma (2019) (22)
MODULAR ANALYTICS: A New Approach to Automation in the Clinical Laboratory (2005) (22)
Quantitative proteomic analysis of ovarian cancer cells identified mitochondrial proteins associated with paclitaxel resistance (2009) (22)
A unique proteolytic fragment of alpha1-antitrypsin is elevated in ductal fluid of breast cancer patient (2010) (21)
Multicentre performance evaluation of the E170 Module for MODULAR ANALYTICS (2004) (21)
Complexed prostate-specific antigen as a staging tool: results based on a multicenter prospective evaluation of complexed prostate-specific antigen in cancer diagnosis. (2002) (21)
Prostate-specific antigen: update 1997. (1997) (21)
Can complexed PSA be used as a single test for detecting prostate cancer? (1999) (19)
Monitoring breast cancer with CA 549. (1988) (19)
Recommendations for mass spectrometry data quality metrics for open access data (corollary to the Amsterdam Principles). (2012) (19)
Variants of prostate-specific antigen separated by concanavalin A. (1991) (19)
Tissue proteomics using chemical immobilization and mass spectrometry. (2015) (19)
Proteomic Analysis of Temporally Stimulated Ovarian Cancer Cells for Biomarker Discovery* (2013) (19)
The chemistry of human transcortin. The effects of pH, urea, salt, and temperature on the binding of cortisol and progesterone. (1977) (18)
An integrated workflow for global, glyco-, and phospho-proteomic analysis of tumor tissues. (2019) (18)
Chapter 1 – General Principle of Immunoassay (1987) (17)
Integration of Network Biology and Imaging to Study Cancer Phenotypes and Responses (2014) (16)
Clinical assessment of a radioimmunoassay for free thyroxine using a modified tracer. (1983) (16)
Impact of a multivariate index assay on referral patterns for surgical management of an adnexal mass. (2013) (16)
Urinary glycoproteins associated with aggressive prostate cancer (2020) (16)
Total, free, and complexed PSA: Analysis and clinical utility (1998) (16)
Multicenter Evaluation of the Performance and Clinical Utility in Longitudinal Monitoring of the Bayer Immuno 1™ Complexed PSA Assay (1999) (16)
Radical prostatectomy as treatment for prostate-specific antigen-detected stage T1c prostate cancer (2005) (15)
The Use of Laser Capture Microscopy in Proteomics Research – A Review (2004) (15)
Modern Tumor Marker Discovery in Urology: Surface Enhanced Laser Desorption and Ionization (SELDI). (2003) (15)
Do Ultrasensitive Prostate Specific Antigen Measurements Have a Role in Predicting Long-Term Biochemical Recurrence-Free Survival in Men after Radical Prostatectomy? (2016) (15)
Elevated urine thrombomodulin/creatinine ratio in severely preeclamptic pregnancies. (1994) (15)
Automated chemiluminescent immunoassay analyzers (1998) (15)
Development of a glycoproteomic strategy to detect more aggressive prostate cancer using lectin-immunoassays for serum fucosylated PSA (2019) (15)
Complexed prostate-specific antigen as a staging tool for prostate cancer: a prospective study in 420 men. (2002) (15)
An integrated proteomic and glycoproteomic approach uncovers differences in glycosylation occupancy from benign and malignant epithelial ovarian tumors (2017) (14)
Proteomic analysis of degradation ubiquitin signaling by ubiquitin occupancy changes responding to 26S proteasome inhibition (2020) (14)
Proteomic signatures of 16 major types of human cancer reveal universal and cancer-type-specific proteins for the identification of potential therapeutic targets (2020) (14)
Development and analytical performance evaluation of an automated chemiluminescent immunoassay for pro-gastrin releasing peptide (ProGRP) (2009) (14)
Rapid parathyroid hormone measurement during venous localization. (2000) (14)
Can volume measurement of the prostate enhance the performance of complexed prostate-specific antigen? (2002) (13)
Bayer immuno 1™ PSA assay: An automated, ultrasensitive method to quantitate total PSA in serum (1998) (13)
PD46-02 MULTICENTER EVALUATION OF THE PROSTATE HEALTH INDEX (PHI) FOR DETECTION OF AGGRESSIVE PROSTATE CANCER IN BIOPSY-NAÏVE MEN (2015) (12)
Monitoring hepatocellular carcinoma by using a monoclonal immunoenzymometric assay for alpha-fetoprotein. (1988) (12)
Ovarian malignancy risk stratification of the adnexal mass using a multivariate index assay (2013) (12)
Biomarkers for Cancer Diagnostics (2008) (12)
Quality control for SELDI analysis (2005) (12)
Proteome-wide Tyrosine Phosphorylation Analysis Reveals Dysregulated Signaling Pathways in Ovarian Tumors* (2018) (12)
Quality Assessments of Long-Term Quantitative Proteomic Analysis of Breast Cancer Xenograft Tissues. (2017) (12)
Integrated analyses of proteins and their glycans in a magnetic bead-based multiplex assay format. (2013) (12)
Immunoassay automation : a practical guide (1994) (11)
MS-PyCloud: An open-source, cloud computing-based pipeline for LC-MS/MS data analysis (2018) (11)
Redesigned proficiency testing materials improve survey outcomes for prostate-specific antigen. A College of American Pathologists Ligand Assay Survey tool. (2000) (11)
Volume indexes of total, free, and complexed prostate-specific antigen enhance prediction of extraprostatic disease extension in men with nonpalpable prostate cancer. (2003) (11)
Generation of PSA-ACT-specific monoclonal antibodies and their application in a sandwich immunoassay. (1999) (11)
Advancing cardiovascular biology and medicine via proteomics: Opportunities and present challenges of cardiovascular proteomics. (2010) (11)
A panel of selected serum protein biomarkers for the detection of aggressive prostate cancer (2021) (11)
Evaluation of the analytical and clinical performance of the Elecsys CA 15-3 immunoassay. (2001) (10)
Clinical instrumentation (immunoassay analyzers). (1995) (10)
THE USE OF % FREE PSA (%fPSA) TO PREDICT PROSTATE CANCER PROBABILITIES: AN ELEVEN CENTER PROSPECTIVE STUDY USING AN AUTOMATED IMMUNOASSAY SYSTEM IN A POPULATION WITH NON-SUSPICIOUS DRE (1999) (10)
ProteinChips: the essential tools for proteomic biomarker discovery and future clinical diagnostics (2005) (10)
Is the WHO 90:10 prostate-specific antigen (PSA) first international reference standard really 90% α1-antichymotrypsin-bound PSA and 10% free PSA? (2011) (10)
Immunosensors—Principles and Applications to Clinical Chemistry (2002) (10)
A NEW MODEL ELISA, BASED ON TWO MONOCLONAL ANTIBODIES, FOR QUANTIFICATION OF FATTY ACID SYNTHASE (2002) (10)
National Academy of Clinical Biochemistry Guidelines for the Use of Tumor Markers in Ovarian Cancer (2006) (9)
Clinical Evaluation Comparing AxSYM® CA 15-3TM, IMx® CA 15-3 and Truquant® BRTM RIA (1998) (9)
Breast cancer marker Ca549. A multicenter study. (1994) (9)
Elecsys TSH, FT4, T4, T-uptake, FT3 and T3. Clinical results of a multicentre study. (1998) (9)
Evaluation of the clinical performance of equimolar- and skewed-response total prostate-specific antigen assays versus complexed and free PSA assays and their ratios in discriminating between benign prostatic hyperplasia and prostate cancer. (2002) (9)
Prostate-specific antigen: advances and challenges. (1999) (9)
Analysis of N-glycoproteins using genomic N-glycosite prediction. (2013) (8)
Comparability of tumor marker immunoassays: still an important issue for clinical diagnostics? (2008) (8)
1847 [-2]PROPSA IN COMBINATION WITH PSA AND FREE-PSA, USING THE BECKMAN COULTER ACCESS IMMUNOASSAY SYSTEMS IMPROVES PROSTATE CANCER DETECTION RELATIVE TO PSA AND FREE PSA. A MULTI-CENTER PROSPECTIVE CLINICAL STUDY (2010) (7)
Analysis of serum protein glycosylation by a differential lectin immunosorbant assay (dLISA) (2013) (7)
Clinical proteomics (2006) (7)
Multicenter evaluation of the Elecsys CA 125 II assay. (1999) (7)
DETECTION OF PROSTATE CANCER WITH %FPSA AND HK2 WHEN PSA IS 2-4 NG/ML (1999) (7)
CA-549: immunohistochemistry and serum levels in breast carcinoma and other neoplasms. (1989) (7)
Analytical and clinical performance characteristics of Hybritech's Tandem-R free PSA assay during a large multicenter clinical trial to determine the clinical utility of percentage of free prostate-specific antigen. (1999) (7)
Will Cancer Proteomics Suffer from Premature Death? (2010) (7)
21 – AUTOMATION OF IMMUNOASSAYS (1996) (7)
Prostate-specific antigen in men born with bladder exstrophy. (1997) (6)
Plasma thrombomodulin levels in women with systemic lupus erythematosus. (1995) (6)
SerumMarkers in Patients with Resectable Pancreatic Adenocarcinoma : Macrophage Inhibitory Cytokine 1 versus CA 19-9 (2006) (6)
Cancer Proteomics: New Developments in Clinical Chemistry. Krebs-„Proteomics": Neue Entwicklungen in der klinischen Chemie (2001) (6)
Improvement and Multicenter Evaluation of the Analytical Performance of an Automated Chemiluminescent Immunoassay for Alpha Fetoprotein (2012) (6)
A large-scale multi-center independent validation study of a panel of seven biomarkers for the detection of ovarian cancer. (2006) (5)
Multicenter evaluation of the Bayer Immuno I CA 15-3 assay. (1998) (5)
Clinical evaluation of two direct procedures for free thyroxin, and of free thyroxin index determined nonisotopically and by measuring thyroxin-binding globulin. (1983) (5)
Specific binding proteins for human chorionic gonadotrophin in a patient with trophoblastic disease. (1981) (5)
Detection of Autoantibodies to Annexin A11 in Different Types of Human Cancer (2009) (5)
CHAPTER 10 – AIA-1200 Immunoassay System (1992) (5)
Clinical evaluation of the Elecsys total prostate-specific antigen assay on the Elecsys 1010 and 2010 systems. (2002) (5)
COMPLEXED PROSTATE SPECIFIC ANTIGEN (cPSA): RESULTS OF A MULTICENTER BIOPSY EXPERIENCE (1999) (5)
PREDIAGNOSTIC SERUM SELENIUM LEVELS AND THE RISK OF PROSTATE CANCER DEVELOPMENT (1999) (5)
Antepartum and Postpartum Thrombomodulin Levels in Preeclamptic and Normotensive Pregnancies (1997) (5)
[-2]proPSA for Prostate Cancer Detection: an NCI Early Detection Research Network Validation Study (2009) (5)
CK-MB isoforms for early risk stratification of emergency department patients. (2000) (4)
Proteomic Analysis of the Air-Way Fluid in Lung Cancer. Detection of Periostin in Bronchoalveolar Lavage (BAL) (2020) (4)
Myoglobin for early risk stratification of emergency department patients with possible myocardial ischemia. (2000) (4)
The chemistry of human transcortin. Improved affinity matrices for the purification of transcortin. (1977) (4)
Mass Spectrometric Identification of Proteotypic Peptides from Clinically Used Tumor Markers (2008) (4)
ANALYSIS OF A SECOND EPCA-2 EPITOPE AS A SERUM TEST FOR PROSTATE CANCER (2008) (4)
1431: Further Analysis of Serum Based EPCA-2 as a Specific Prostate Cancer Associated Biomarker (2007) (4)
Elecsys CEA, PSA and AFP. Clinical results of a multicentre evaluation. (1998) (4)
CANCER DETECTION RATE FOR PATIENTS WITH TOTAL PSA CONCENTRATIONS <4 NG/ML: COMPARISON OF TOTAL, FREE, AND COMPLEXED PSA (1999) (3)
The Value of Prostatic Specific Antigen in the Management of Adenocarcinoma of the Prostate (1987) (3)
Bone to total alkaline phosphatase ratios improve sensitivity and specificity of bone alkaline phosphatase immunoassays. (1997) (3)
Serum separator tube problems in Hitachi 736/737 analyzers. (1989) (3)
Retraction: Evaluation of Colon Cancer-Specific Antigen 2 as a Potential Serum Marker for Colorectal Cancer (2012) (3)
Detection of Uveal Melanoma by Multiplex Immunoassays of Serum Biomarkers. (2021) (3)
Automation of thyroid function testing. (1993) (3)
Comparison of total prostate-specific antigen and derivative levels in a screening population of black, white, and Korean-American men. (2003) (3)
Automated quantification of choriogonadotropin: analytical correlation between serum and urine with creatinine correction. (1987) (3)
Validation of Serum Biomarkers That Complement CA19-9 in Detecting Early Pancreatic Cancer Using Electrochemiluminescent-Based Multiplex Immunoassays (2021) (3)
Does preeclamptic pregnancy increase fetal-maternal hemorrhage? (1995) (3)
for the Detection of Early Stage Ovarian Cancer Three Biomarkers Identified from Serum Proteomic Analysis (2004) (3)
Development and evaluation of the MiCheck test for aggressive prostate cancer. (2020) (3)
Predicting cancer on repeat biopsy: Results of a multicenter prospective evaluation of complexed PSA (2003) (3)
Investigation of human anti-mouse antibodies as potential cause of postprostatectomy PSA elevation. (2009) (3)
Choosing an Automated Immunoassay System (2013) (3)
The value of prostate-specific antigen in the management of localized prostatic cancer. (1989) (3)
Results of a multicenter prospective evaluation of complexed PSA (2002) (2)
Evaluation of Beckman electrolyte 2 analyzer using ion-selective sodium and potassium electrodes (1984) (2)
Endocrine assays in the monitoring of pregnancy. (1981) (2)
Malignancy-associated endocrine disorders (2021) (2)
Circulating thrombomodulin levels and clinical correlates in pregnant diabetics. (1997) (2)
Clinical instrumentation (immunoassay analyzers) : Clinical chemistry (1995) (2)
Decoding the Folding Patterns of Serum Proteins: An Alternative Strategy for Cancer Biomarker Validation? (2010) (2)
2055 PROSTATE HEALTH INDEX (PHI) FOR REDUCING OVERDETECTION OF INDOLENT PROSTATE CANCER AND UNNECESSARY BIOPSY WHILE IMPROVING DETECTION OF AGGRESSIVE CANCERS (2013) (2)
The effects of modifying proficiency testing materials on thyroid function test results. A College of American Pathologists Ligand Assay Survey Study. (1997) (2)
DIFFERENCES IN PSA MEASUREMENTS DUE TO ASSAY STANDARDIZATION BIAS (2008) (2)
CHAPTER 2 – Automation of Immunoassay (1992) (2)
Proteome-wide Tyrosine Phosphorylation Analysis Reveals Dysregulated Signaling Pathways in Ovarian Tumors. (2019) (1)
Derivation of a second generation multivariate index assay to improve specificity in pre-surgical evaluation of adnexal masses for risk of ovarian malignancy. (2015) (1)
Proteogenomic Characterization of Ovarian HGSC Implicates Mitotic Kinases, Replication Stress in Observed Chromosomal Instability (2020) (1)
Prostate-specific antigen : Its discovery and biochemical characteristics : Prostate-specific antigen: the best prostatic tumor marker (1997) (1)
Cancer Biomarker Assays: Performance Standards (2017) (1)
Altered circulating thrombomodulin levels and antithrombin-III activity as evidence for varied activation of the coagulation cascade in severely versus mildly preeclamptic pregnancies (1995) (1)
Protein identification and immunoassay evaluation of a panel of biomarkers discovered through proteomic profiling for the detection of ovarian cancer (2004) (1)
Correction to: Proteomic analysis of degradation ubiquitin signaling by ubiquitin occupancy changes responding to 26S proteasome inhibition (2020) (1)
CHAPTER 9 – Affinity Immunoassay System (1992) (1)
Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges (2013) (1)
MEASUREMENT OF TROPONIN I (TnI) WITH CK-MB IMPROVES DETECTION OF PERIOPERATIVE ISCHEMIA (1998) (1)
Increased Plasma DNA Integrity in Cancer Patients 1 (2003) (1)
[-2]PROPSA FOR PROSTATE CANCER DETECTION: A PROSPECTIVE, MULTICENTER, NCI EARLY DETECTION RESEARCH NETWORK STUDY (2009) (1)
Circulating thrombomodulin levels and clinical correlates in pregnant diabetics (1997) (1)
Clinical proteomics: Cancer diagnostics? (2005) (1)
A Targeted Proteomics Approach for Biomarker Discovery Using Bilateral Matched Nipple Aspiration Fluids (2010) (1)
PROSTATE-SPECIFIC ANTIGEN DOUBLING TIME (PSADT), GLEASON SCORE AND THE TIME TO PSA RECURRENCE FOLLOWING RADICAL PROSTATECTOMY PREDICTS TIME TO DISTANT PROGRESSION (1999) (1)
MP40-13 OPTIMIZED CLINICAL ALGORITHM TO COMBINE TESTING OF SERUM PHI AND URINARY PCA3 TO IMPROVE PROSTATE CANCER DETECTION BY REDUCING UNNECESARY BIOPSY (2018) (1)
Abstract 5123: Proteogenomic characterization reveals mitotic kinase and replication stress implicated in ovarian high-grade serous cancer (2020) (1)
A panel of biomarkers to improve specificity in presurgical assessment of adnexal masses for risk of ovarian malignancy. (2013) (1)
982 EVALUATION OF THE PROSTATE HEALTH INDEX (PHI)1 IN THE 2 TO 4, AND 4 TO 10 NG/ML PSA RANGES: RESULTS FROM A MULTI-SITE, PROSPECTIVE, CLINICAL EVALUATION (2011) (1)
PI-08 COMBINING URINE PCA3 AND TMPRSS2: ERG TESTS TO REFINE PROSTATE CANCER DETECTION – VALIDATION STUDY AND HEALTH ECONOMIC ANALYSIS (2015) (1)
Analytical performance of an automated immunoassay for tissue inhibitor of me talloproteinases-1 (TIMP-1) (2007) (1)
Utility of Three-Protein Panels in the Separation of Aggressive Prostate Cancer from Non-Aggressive Tumors (2021) (0)
Interference in T3 (RIA) caused by T1-201 (1979) (0)
Specific Binding Proteins for Human Chorionic Gonadotrophin in a Patient With Trophoblastic Disease (1982) (0)
0255: Validation of a Panel of Seven Proteomic Bio-Markers in an Independent and Blinded Sample Set (2006) (0)
CHAPTER 3 – Selection of Automated Immunoassay Systems (1992) (0)
Abstract 1268: Accurate measurement of serum total and free PSA using immunoaffinity depletion coupled to SRM: Correlation with clinical immunoassays (2012) (0)
INCIDENCE OF PERIOPERATIVE MYOCARDIAL INJURY BASED ON ACC/AHA GUIDELINES FOR PERIOPERATIVE CARDIOVASCULAR EVALUATION FOR NON-CARDIAC SURGERY (1998) (0)
Tumour markers in practice: case studies (2019) (0)
A. M. Lawson, C. K. Lim, W. Richmond (EDS). Current developments in the clinical applications of HPLC, GC and MS. Academic Press, London, 1980 (1982) (0)
Performance of solid-state 48 detector gamma counter using solid phase total thyroxin and free thyroxin assays. (1986) (0)
CHAPTER 4 – Technical Evaluation (1992) (0)
Measurement of urinary estriol by radio immunoassay procedures using simultaneous enzymatic hydrolysis and radio immunoassay (1980) (0)
SCI€NTIFIC ADVANC€S The Prognostic Significance of Troponin I and soponin T (1998) (0)
Use of biomarkers for evidence of ovarian cancer (2003) (0)
Clinical chemistry. (1997) (0)
MP35-06 MULTI-CENTER PROSPECTIVE STUDY OF PROSTATE HEALTH INDEX (PHI) TESTING AS A STRATEGY FOR PROSTATE CANCER SCREENING: COLLABORATION BETWEEN UROLOGY, PRIMARY CARE, AND COMMUNITY OUTREACH (2018) (0)
0288: A Panel of Seven Biomarkers Improves Specificity in Discriminating Malignant From Benign Pelvic Masses (2006) (0)
A new approach to free thyroxine measurement by RIA: Laboratory and clinical assessment (1981) (0)
Evaluation ofa Monoclonal lmmunoenzymometric AssayforAlpha- Fetoprotein (1986) (0)
Room 302, 10/18/2000 9: 00 AM - 10: 30 AM (PD) Detection of Perioperative Ischemia is Improved by Troponin (TnI) Measurement A-253 (2000) (0)
Circulating interleukin-1 as a clinical marker in pregnant diabetics (1995) (0)
Simultaneous determination of valproate and ethosuximide by gas-liquid chromatography (1979) (0)
Determination of bilirubin in pediatric samples: a re-examination of the discrepancy between spectrophotometric and chemical methods. (1979) (0)
4058 Enhanced efficiency of large-scale clinical proteomic studies: when less is more (2020) (0)
Abstract B1-26: NetFill: A network-based method to identify a parsimonious set of mediators to link mRNA and protein signatures using existing knowledge (2015) (0)
CHAPTER 5 – Clinical Evaluation (1992) (0)
Abstract 208: Proteomic measurements of protein abundance and phosphorylation identify novel kinase-substrate relationships in ovarian cancer (2017) (0)
128 Serum concentrations of human glandular kallikrein 2 (HK2) but not free PSA, total PSA or %FPSA permit discrimination of pathologically organ-confined (OC) from non-organ confined (NOC), non-palpable (clinical stage T1C) prostate cancer (2004) (0)
Immunologic Approaches to Tumor Markers: Assays, Applications, and Discovery (2006) (0)
CHAPTER 8 – Introduction of Automated Immunoassay Systems (1992) (0)
CHAPTER 6 – Operational Evaluation (1992) (0)
in press-uncorrected proof A comparative evaluation of Golgi protein-73 , fucosylated hemopexin , a-fetoprotein , and PIVKA-II in the serum of patients with chronic hepatitis , cirrhosis , and hepatocellular carcinoma (2011) (0)
Immunoassay automation at the millennium (1999) (0)
Multicentre evaluation of the Boehringer Mannheim Elecsys 2010 immunoassay system, workshop Vilamoura/Portugal, October 17-18, 1996 (1998) (0)
The Measurement of Amylase Using a Fluorescent Depolarization Assay on the Abbott TDx Analyzer (1988) (0)
860: Protein C Inhibitor as a Biomarker for Prostate Cancer: Detection, Staging, and Prediction of Recurrence (2006) (0)
Earlydetectionofcancer: immunoassaysforplasmatumor markers (2009) (0)
Identifying Markers for Pancreatic Cancer by Gene Expression 1 (2005) (0)
Serum angiotensin converting enzyme activity in pregnancy-induced hypertension (1997) (0)
Abstract 5118: Proteogenomics characterization of HPV-negative head and neck squamous cell carcinomas (2020) (0)
An evaluation of three radioimmunoassay kits for serum prolactin (1979) (0)
Development of magnetic bead-based multiplex immunoassays to evaluate serum biomarkers for the early detection of pancreatic cancer (2015) (0)
Tumor Markers: Physiology, Patho-biology, Technology and Clinical (2003) (0)
Biomarkers for ovarian cancer: Related proteins ctap3 (2006) (0)
Overview of immunodiagnostics for tumor markers (1989) (0)
Altered circulating thrombomodulin and fibronectin levels as evidence for different degrees of vascular endothelial damage between severe and mild preeclampsia (1995) (0)
0190: A Panel of Seven Biomarkers Improves Detection of Ovarian Cancer (2006) (0)
Abstract 4816: OVA1: An in vitro diagnostic multivariate index assay for preoperative assessment of ovarian tumors (2010) (0)
Network analysis reveals a dominant role of protein-level regulation in coordinating gene functions (2016) (0)
MiCheck prostate blood test for aggressive prostate cancer designed for the clinical lab setting. (2022) (0)
1411: Serum Biomarker Discovery using Proteomics Approaches to Predict Prostate Cancer Recurrence (2005) (0)
PD46-05 MULTI-CENTER PROSPECTIVE STUDY OF URINE RNA TESTING AS A STRATEGY FOR PROSTATE CANCER SCREENING: COLLABORATION BETWEEN UROLOGY, PRIMARY CARE, AND COMMUNITY OUTREACH (2015) (0)
1659: Effects of Finasteride and Saw Palmetto on BPSA, Propsa, and cPSA in Men with Benign Prostatic Hyperplasia (2004) (0)
Biomarqueurs destines a la detection du cancer de l'ovaire (2003) (0)
Retraction. Initial analyses of colon cancer-specific antigen (CCSA)-3 and CCSA-4 as colorectal cancer-associated serum markers. (2013) (0)
Clinical Assessment of a Radioimmunoassayfor Free Thyroxine Using a ModifiedTracer (2006) (0)
Understanding immunoassay: A practical guide (2019) (0)
CHAPTER 7 – Economical Evaluation (1992) (0)
Validation of Breast Cancer Biomarkers Identified by Mass Spectrometry: Some of the authors of the article cited above respond: (2006) (0)
Surrogate endpoints in the management of acute myeloid leukemia (2005) (0)
An assessment of Stat Tek: a reagent-strip method for glucose determination. (1980) (0)
Performance evaluation of the kineticount 48 gamma counter and solid phase reagents for T4 and free T4 (1984) (0)
Measurement of urinary estriol by RIA: Procedures using simultaneous hydrolysis and radioimmunoassay (1980) (0)
Identifying Markers for Pancreatic Cancer by Gene (2017) (0)
61 CLINICAL UTILITY OF THE IMx® TACROLIMUS II (FK506) ASSAY (1997) (0)
137 EVALUATION OF [-2]PROPSA IN COMBINATION WITH PSA AND FREE PSA, USING THE BECKMAN COULTER ACCESS IMMUNOASSAY SYSTEMS, FOR IDENTIFYING PATIENTS WITH AGGRESSIVE PROSTATE CANCER. A MULTI-CENTER PROSPECTIVE CLINICAL EVALUATION (2010) (0)
W1889 Blood-Based Detection of Colon Cancer Utilizing Specific Nuclear Matrix Proteins (2009) (0)
Title Impact of a multivariate index assay on referral patterns for surgical management of an adnexal mass Permalink (2013) (0)
Exciting news from Clinical Proteomics (2011) (0)
Basic fibroblastic growth factor in human prostate cancer: in vitro and human studies of radiation-induced modulation (2000) (0)
Decision tree algorithms for prostate cancer detection Complexed PSA and other significant predictors using CHAID analysis (2002) (0)
SERUM SELDI-TOF-MS PROTEOMICS FOR NOVEL MARKERS FOR OVARIAN CANCER (2004) (0)
The success of precision pathology: Multi-omics building blocks (2019) (0)
Non-isotopic immunoassays for thyroxine (1980) (0)
822: The Influence of Recurrent Prostate Cancer on Serum Testosterone Levels (2005) (0)
CORRELATION BETWEEN QUANTITATIVE TISSUE PROSTATE SPECIFIC ANTIGEN (PSA) IMMUNOHISTOCHEMISTRY (IHC) AND SERUM LEVELS OF PSA (1999) (0)
Radioimmunoassay of estetrol (E4): A more sensitive indicator of fetal morbidity than estriol (E3) (1979) (0)
Identification of biomarkers to improve specificity in preoperative assessment of ovarian tumor for risk of cancer (2011) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Daniel Wan-yui Chan?

Daniel Wan-yui Chan is affiliated with the following schools: